

ORYZON to present at two US investor conferences

- **Oryzon to present for the first time at NobleCon14, Noble Capital Markets' Fourteenth Annual Investor Conference in Fort Lauderdale, Florida**
- **Oryzon to present at the 20th Annual BIO CEO & Investor Conference 2018 in New York**

MADRID, SPAIN and CAMBRIDGE, MA, January 23, 2018 – Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that its CEO, Dr. Carlos Buesa, will present the recent progresses of the company at NobleCon14 - Noble Capital Markets' Fourteenth Annual Investor Conference - at the W Hotel, Fort Lauderdale, Florida on Tuesday, January 30th at 13:00 EST. A high-definition, video webcast of the presentation will be available the following day on the company's web site www.oryzon.com and as part of a complete catalog of presentations available at Noble Capital Markets' websites: www.noblecapitalmarkets.com and www.nobleconference.com.

Dr. Buesa will also present at the 2018 BIO CEO & Investor Conference being held on February 12-13 at the New York Marriott Marquis in New York City. The presentation will take place on Tuesday, February 13th at 14:45 EST in the Ziegfield Room within the CNS/Neurological Therapeutic Area.

The company has recently reported in several scientific conferences that ORY-2001 exerts a holistic action in the different alterations seen in patients suffering from AD and other neurodegenerative disorders. Different experiments suggest that ORY-2001 acts as a disease modifying drug. In AD patients and other neurodegenerative disorders, cognitive deterioration is often accompanied by episodes of agitation, aggression, psychosis, apathy and depression. In preclinical studies, ORY-2001 not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice to normal levels and also reduces social avoidance in rat models maintained in isolation. After proving safety in the 9 month preclinical regulatory tox studies, ORY-2001 demonstrated safety and tolerability in a Phase I clinical trial conducted with 106 healthy volunteers that allowed to establish the doses for Phase II in patients. The company recently received the approval to carry out a Phase IIA with ORY-2001 in patients with multiple sclerosis (MS) and plans to request soon the corresponding authorizations for a Phase IIA clinical trial in patients with Alzheimer's disease. New scientific data on ORY-2001 will also be presented in two posters at the ACTRIMS Forum 2018, which will take place in San Diego on February 1-3.

Epigenetic approaches to modify the progression of various neurodegenerative diseases, which focus on the production of changes in gene expression patterns in brain cells, have generated interest in the pharmaceutical industry.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field. Oryzon's LSD1 program has resulted in + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Spain and USA. For more information, visit www.oryzon.com.

About Noble Capital Markets, Inc.

Noble Capital Markets, established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique. The company has offices in Boca Raton, New York, Boston and St. Louis. In addition to NobleCon - the annual multi-sector investor conference - and the Media, Finance & Investor Program, produced in partnership with the National Association of Broadcasters (NAB) and held each spring in Las Vegas, throughout the year Noble hosts numerous "non-deal" corporate road shows across the United States and Canada. Members: FINRA, SIPC, MSRB. www.noblecapitalmarkets.com

About the BIO CEO & Investor Conference

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded biotech companies. The conference's mission is to support industry-wide success, and to present a broad and unbiased view of investment opportunities. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the *Comisión Nacional del Mercado de Valores*, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A. have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to

publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States. The Company's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company's securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

US Contact:**The Trout Group****Thomas Hoffmann**

+1 646 378 2932

thoffmann@troutgroup.com**Spain:****ATREVIA****Patricia Cobo/Luis Rejano**

+34 91 564 07 25

pcobo@atrevia.com**lrejano@atrevia.com****The Company:****Emili Torrell****BD Director**

+34 93 515 13 13

etorrell@oryzon.com